血管内皮细胞生长因子受体酪氨酸激酶抑制剂的研究进展  

Investigations in vascular endothelial growth factor receptor family tyrosine kinase inhibitor

作　　者：钟毅[1] 李志裕[1] 尤启冬[1] 

机构地区：[1]中国药科大学药物化学教研室,南京210009

出　　处：《中国新药杂志》2006年第3期181-185,共5页Chinese Journal of New Drugs

基　　金：中国药科大学青年教师基金(A0204)

摘　　要：血管内皮细胞生长因子受体(VEGFR)家族的受体酪氨酸激酶与多种恶性肿瘤的发生、发展及预后等密切相关。近年来,许多以此为靶点的新的抗肿瘤药物和治疗方法陆续被开发。综述了作用于VEGFR的酪氨酸激酶抑制剂bevacizumab,PTK787,BAY 43-9006,SU11248和ZD6474的研究进展。The tyrosine kinase levels of vascular endothelial growth factor receptor （VEGFR） family are closely associated with incidence, metastasis and prognosis of many kinds of malignant tumor. A few of the VEGFR-targeted antineoplastic therapies have been impressively developed in passing years. This article briefly introduced VEGFR status and summarized the investigations of VEGFR family tyrosine kinase inhibitors, such as bevacizumab, PTK787, BAY 43-9006. SU11248 and ZD6474

关 键 词：血管内皮细胞生长因子受体 受体酪氨酸激酶 肿瘤 

分 类 号：R977.3[医药卫生—药品] R979.1[医药卫生—药学]